This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months. Approximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 3 will enroll approximately 8 participants randomized into Cohort 3a or Cohort 3b. Cohort 3a will receive the high dose prime VRON-0200 vaccination of vector AdC7 on Day 1, followed by doses of VIR-2218 plus VIR-3434 on Days 28, 56, 84, 112, 140 and 168, and then a booster using a high dose VRON-0200 vaccination of vector AdC6 on Day 196. Cohort 3b will receive the same high dose prime VRON-0200 vaccination of vector AdC7 followed by 6 doses of VIR-2218 plus VIR-3434 at the same timepoints as Cohort 3a, but will not receive the booster dose on Day 196. VRON-0200 vaccine doses will be administered by intramuscular (IM) injection. VIR-2218 and VIR-3434 will be administered subcutaneously. All study participants will be followed for a total of 1 year post-prime vaccination.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
35
VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
Chinese University of Hong Kong
Hong Kong, Hong Kong
Aotearoa Clinical Trials, Middlemore Hospital
Auckland, New Zealand
Auckland City Hospital
Auckland, New Zealand
Treatment Emergent Adverse Events
Number and percent of participants with 1 or more treatment-emergent adverse events within 28 days after the last dose by cohort.
Time frame: 28 days
Grade 3 Adverse Events
Number and percent of participants with Grade 3 or higher local and/or systemic reactions within 28 days after the last dose by cohort.
Time frame: 28 days
Clinically Significant Changes in Lab Values
Number and percent of participants with clinically significant changes from pre-vaccination laboratory values within 28 days after the last dose by cohort.
Time frame: 28 days
Serious Adverse Events
Number and percent of participants with serious adverse events within 6 months after the last dose by cohort.
Time frame: 6 months
Medically Attended Adverse Events
Number and percent of participants with medically attended adverse events within 6 months after the last dose by cohort.
Time frame: 6 months
Adverse Events
Number and percentage of adverse events for all participants through Day 360.
Time frame: 360 days
T Cell Frequencies
Change from baseline in vaccine-induced CD8+ T cell frequencies in the blood.
Time frame: 360 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.